Lancet:婴儿早期抗逆转录病毒治疗后常规HIV抗体测试

2015-06-02 MedSci MedSci原创

背景:早期抗逆转录病毒疗法(ART)和病毒学抑制会影响进化的抗体对HIV感染的反应。该研究的目的是评估婴儿血清阴性早期ART治疗的频率和预测。    方法:研究人员对治疗艾滋病的早期抗逆转录病毒疗法(CHER)试验中的三个组进行了两两比较,从2005年7月开始,2011年7月完成。在这个试验中,5.7-12.0周感染HIV,并有至少25%的CD4阳性T淋巴细胞的婴儿被

背景:早期抗逆转录病毒疗法(ART)和病毒学抑制会影响进化的抗体对HIV感染的反应。该研究的目的是评估婴儿血清阴性早期ART治疗的频率和预测。
    
方法:研究人员对治疗艾滋病的早期抗逆转录病毒疗法(CHER)试验中的三个组进行了两两比较,从2005年7月开始,2011年7月完成。在这个试验中,5.7-12.0周感染HIV,并有至少25%的CD4阳性T淋巴细胞的婴儿被随机分配到即时ART 96周(ART-96W)或推迟ART治疗直到有临床或免疫学进展(ART-Def)。研究人员在试验第84周用3次检测对ART-96W和ART-Def储存的样本进行了抗体检测:第四代酶联免疫HIV抗原抗体结合,HIV-1和HIV-2抗体的快速检测,ELISA定量的抗-gp120抗体。研究人员还评估了和累积病毒载量以及ART开始治疗时的婴儿年龄有关的血清阳性的几率。
    
结果:从开始作为样本时开始婴儿的(184例样本来自于268名婴儿)中位年龄为92周(IQR 90.6–93.4)。采用酶免疫分析法得到ART-96W组比ART-Def有更多的血清阴性(ART-96W 107例中有49例[ 46% ] vs ART-Def 75例中有8例[11%];P<0.0001),快速抗体检测(101例中有54例[53%] vs 74例中有8例[11%];P<0.0001)。在ART-96W组中位抗-gp120 IgG浓度(230μg/μL [IQR 133-13129 ])比ART-Def组(6870μg/μL [1706–53645 ];P<0.0001)低。如果ART是在婴儿12周和24周之间开始的,与在婴儿年龄为0周和12周之间开始时相比,血清阳性率提高了13.7倍(95% Cl 3.1–60.2;P = 0.001)。所有的婴儿在开始ART时的年龄都超过了24周。84周时的累积病毒载量与抗-gp120 IgG浓度(系数0.54;P<0.0001)和阳性的几率增加(比值比1.59,[95% Cl 1.1-2.3]有关,对ART开始时的年龄进行了调整。
    
结论:大约一半的婴儿在12周龄前开始ART,近2岁时HIV为阴性。HIV抗体测试不能用来再次确认儿童早期ART的HIV诊断。抗体阴性的长期疗效需要进一步研究。重新测试与改进的诊断测试的需要清晰的指引。

原始出处:

Dr Helen Payne, MBChBcorrespondenceemail, Nonhlanhla Mkhize, PhD, Kennedy Otwombe, MSc, Joanna Lewis, PhD, Ravindre Panchia, MBBCh, Robin Callard, PhD, Lynn Morris, DPhil, Abdel Babiker, PhD, Avy Violari, FCPaed [SA], Mark F Cotton, PhD, Nigel J Klein, PhD, Diana M Gibb, MD,Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial,Lancet,2015.6.1

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747191, encodeId=6ae81e4719193, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Feb 21 20:36:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688275, encodeId=aab816882e5e2, content=<a href='/topic/show?id=e1875580689' target=_blank style='color:#2F92EE;'>#抗逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55806, encryptionId=e1875580689, topicName=抗逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05c928519131, createdName=ms1292405679162969, createdTime=Thu Mar 17 07:36:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926827, encodeId=7b30192682e90, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Fri Jul 24 22:36:00 CST 2015, time=2015-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053168, encodeId=e5d12053168f1, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat Dec 26 07:36:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828131, encodeId=c54718281317e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon May 09 21:36:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036524, encodeId=eeab20365249c, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Dec 02 03:36:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554347, encodeId=5a0a155434e2f, content=<a href='/topic/show?id=d4bf5580e02' target=_blank style='color:#2F92EE;'>#抗逆转录病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55807, encryptionId=d4bf5580e02, topicName=抗逆转录病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=804c14523313, createdName=crystal0567, createdTime=Thu Jun 04 07:36:00 CST 2015, time=2015-06-04, status=1, ipAttribution=)]
    2016-02-21 mjldent
  2. [GetPortalCommentsPageByObjectIdResponse(id=1747191, encodeId=6ae81e4719193, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Feb 21 20:36:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688275, encodeId=aab816882e5e2, content=<a href='/topic/show?id=e1875580689' target=_blank style='color:#2F92EE;'>#抗逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55806, encryptionId=e1875580689, topicName=抗逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05c928519131, createdName=ms1292405679162969, createdTime=Thu Mar 17 07:36:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926827, encodeId=7b30192682e90, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Fri Jul 24 22:36:00 CST 2015, time=2015-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053168, encodeId=e5d12053168f1, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat Dec 26 07:36:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828131, encodeId=c54718281317e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon May 09 21:36:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036524, encodeId=eeab20365249c, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Dec 02 03:36:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554347, encodeId=5a0a155434e2f, content=<a href='/topic/show?id=d4bf5580e02' target=_blank style='color:#2F92EE;'>#抗逆转录病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55807, encryptionId=d4bf5580e02, topicName=抗逆转录病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=804c14523313, createdName=crystal0567, createdTime=Thu Jun 04 07:36:00 CST 2015, time=2015-06-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1747191, encodeId=6ae81e4719193, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Feb 21 20:36:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688275, encodeId=aab816882e5e2, content=<a href='/topic/show?id=e1875580689' target=_blank style='color:#2F92EE;'>#抗逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55806, encryptionId=e1875580689, topicName=抗逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05c928519131, createdName=ms1292405679162969, createdTime=Thu Mar 17 07:36:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926827, encodeId=7b30192682e90, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Fri Jul 24 22:36:00 CST 2015, time=2015-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053168, encodeId=e5d12053168f1, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat Dec 26 07:36:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828131, encodeId=c54718281317e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon May 09 21:36:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036524, encodeId=eeab20365249c, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Dec 02 03:36:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554347, encodeId=5a0a155434e2f, content=<a href='/topic/show?id=d4bf5580e02' target=_blank style='color:#2F92EE;'>#抗逆转录病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55807, encryptionId=d4bf5580e02, topicName=抗逆转录病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=804c14523313, createdName=crystal0567, createdTime=Thu Jun 04 07:36:00 CST 2015, time=2015-06-04, status=1, ipAttribution=)]
    2015-07-24 hxj0117
  4. [GetPortalCommentsPageByObjectIdResponse(id=1747191, encodeId=6ae81e4719193, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Feb 21 20:36:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688275, encodeId=aab816882e5e2, content=<a href='/topic/show?id=e1875580689' target=_blank style='color:#2F92EE;'>#抗逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55806, encryptionId=e1875580689, topicName=抗逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05c928519131, createdName=ms1292405679162969, createdTime=Thu Mar 17 07:36:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926827, encodeId=7b30192682e90, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Fri Jul 24 22:36:00 CST 2015, time=2015-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053168, encodeId=e5d12053168f1, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat Dec 26 07:36:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828131, encodeId=c54718281317e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon May 09 21:36:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036524, encodeId=eeab20365249c, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Dec 02 03:36:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554347, encodeId=5a0a155434e2f, content=<a href='/topic/show?id=d4bf5580e02' target=_blank style='color:#2F92EE;'>#抗逆转录病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55807, encryptionId=d4bf5580e02, topicName=抗逆转录病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=804c14523313, createdName=crystal0567, createdTime=Thu Jun 04 07:36:00 CST 2015, time=2015-06-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1747191, encodeId=6ae81e4719193, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Feb 21 20:36:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688275, encodeId=aab816882e5e2, content=<a href='/topic/show?id=e1875580689' target=_blank style='color:#2F92EE;'>#抗逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55806, encryptionId=e1875580689, topicName=抗逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05c928519131, createdName=ms1292405679162969, createdTime=Thu Mar 17 07:36:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926827, encodeId=7b30192682e90, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Fri Jul 24 22:36:00 CST 2015, time=2015-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053168, encodeId=e5d12053168f1, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat Dec 26 07:36:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828131, encodeId=c54718281317e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon May 09 21:36:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036524, encodeId=eeab20365249c, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Dec 02 03:36:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554347, encodeId=5a0a155434e2f, content=<a href='/topic/show?id=d4bf5580e02' target=_blank style='color:#2F92EE;'>#抗逆转录病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55807, encryptionId=d4bf5580e02, topicName=抗逆转录病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=804c14523313, createdName=crystal0567, createdTime=Thu Jun 04 07:36:00 CST 2015, time=2015-06-04, status=1, ipAttribution=)]
    2016-05-09 howi
  6. [GetPortalCommentsPageByObjectIdResponse(id=1747191, encodeId=6ae81e4719193, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Feb 21 20:36:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688275, encodeId=aab816882e5e2, content=<a href='/topic/show?id=e1875580689' target=_blank style='color:#2F92EE;'>#抗逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55806, encryptionId=e1875580689, topicName=抗逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05c928519131, createdName=ms1292405679162969, createdTime=Thu Mar 17 07:36:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926827, encodeId=7b30192682e90, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Fri Jul 24 22:36:00 CST 2015, time=2015-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053168, encodeId=e5d12053168f1, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat Dec 26 07:36:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828131, encodeId=c54718281317e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon May 09 21:36:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036524, encodeId=eeab20365249c, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Dec 02 03:36:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554347, encodeId=5a0a155434e2f, content=<a href='/topic/show?id=d4bf5580e02' target=_blank style='color:#2F92EE;'>#抗逆转录病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55807, encryptionId=d4bf5580e02, topicName=抗逆转录病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=804c14523313, createdName=crystal0567, createdTime=Thu Jun 04 07:36:00 CST 2015, time=2015-06-04, status=1, ipAttribution=)]
    2015-12-02 Homburg
  7. [GetPortalCommentsPageByObjectIdResponse(id=1747191, encodeId=6ae81e4719193, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Feb 21 20:36:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688275, encodeId=aab816882e5e2, content=<a href='/topic/show?id=e1875580689' target=_blank style='color:#2F92EE;'>#抗逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55806, encryptionId=e1875580689, topicName=抗逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05c928519131, createdName=ms1292405679162969, createdTime=Thu Mar 17 07:36:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926827, encodeId=7b30192682e90, content=<a href='/topic/show?id=09d594e5610' target=_blank style='color:#2F92EE;'>#逆转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94756, encryptionId=09d594e5610, topicName=逆转录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Fri Jul 24 22:36:00 CST 2015, time=2015-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053168, encodeId=e5d12053168f1, content=<a href='/topic/show?id=623294e587c' target=_blank style='color:#2F92EE;'>#逆转录病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94758, encryptionId=623294e587c, topicName=逆转录病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat Dec 26 07:36:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828131, encodeId=c54718281317e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon May 09 21:36:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036524, encodeId=eeab20365249c, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Dec 02 03:36:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554347, encodeId=5a0a155434e2f, content=<a href='/topic/show?id=d4bf5580e02' target=_blank style='color:#2F92EE;'>#抗逆转录病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55807, encryptionId=d4bf5580e02, topicName=抗逆转录病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=804c14523313, createdName=crystal0567, createdTime=Thu Jun 04 07:36:00 CST 2015, time=2015-06-04, status=1, ipAttribution=)]

相关资讯

Lancet:抗逆转录病毒治疗可降低HIV传播

  来自北京大学、中国疾病预防控制中心、哈佛大学和中国海洋大学等研究机构的研究人员近日在《柳叶刀》(The lancet)上发布了一项全国性观察组群研究的结果,报告了2003-2011年中国不一致夫妇(serodiscordant couples)抗逆转录病毒治疗预防HIV传播的情况。   领导这一研究的是中国疾病预防控制中心艾滋病首席专家、性病艾滋病预防控制中心病毒与免疫研究室主任邵一鸣教授。

临床艾滋病治疗再传新捷报

两名美国波士顿的HIV感染者在接受干细胞移植治疗淋巴瘤后,他们的艾滋病有可能也得到了治愈。在吉隆坡召开的国际艾滋病大会上两人的医生公布了这一消息。 两名男子大约分别在3年前和5年前,接受了干细胞移植以替换造血骨髓。他们的治疗方案与“柏林患者” Timothy Ray Brown相似。Brown是唯一宣称HIV治愈的成人患者,6年来他的体内都未再检测到HIV病

Lancet Infect Dis:对于 HIV-1 应采用早期还是延迟抗逆转录病毒疗法?

背景使用抗逆转录病毒治疗 HIV-1 感染降低了 AIDS-相关发病率和死亡率,并防止了 HIV-1 的性传播。 但是,出于减少 HIV-1感染进展或非-AIDS 临床事件的目的,开始抗逆转录病毒治疗的最佳时间尚属未知。 我们此前曾报告早期抗逆转录病毒治疗可将 HIV-1 传播减少96%。 我们的研究目的是:比较早期与延迟开始抗逆转录病毒治疗对临床预后的影响。方法HPTN 052 试验是一项在九个

Nature:HIV感染者体内病毒储存库的建立极早

病毒储存库的存在是治愈HIV-1感染的一个最主要障碍,HIV病毒可以在细胞中潜伏多年,逃避抗逆转录病毒药物的破坏效应。然而,对于急性HIV感染过程中病毒储存库建立的时间和地点,或是它们对于早期抗逆转录病毒治疗(ART)的敏感程度人们却知之甚少。现在,由贝斯以色列女执事医疗中心(BIDMC)以及美国军方艾滋病研究项目的研究人员领导的一个研究小组,证实在猕猴直肠内感染猴免疫缺陷病毒(SIV)之后,可检